Skip to main content
. 2022 Nov 1;12(11):e065217. doi: 10.1136/bmjopen-2022-065217

Figure 1.

Figure 1

Safety reporting flow chart for the ImpresU clinical trial. *A follow-up report should be submitted in writing within 48 hours. **Follow-up information to be provided in further 8 days. AE, adverse event; PI, principal investigator; SAE, serious adverse event; SAR, serious adverse drug reaction; SUSAR, suspected unexpected serious adverse reaction; UTI, urinary tract infection.